ARAY
Accuray Incorporated [ARAY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ARAY Stock Summary
Top 10 Correlated ETFs
ARAY
Top 10 Correlated Stocks
ARAY
In the News
Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
Accuray Incorporated - Impressive Growth As Orders Expands
Accuray Incorporated has shown impressive growth in its share price and revenues, making it an attractive investment opportunity in the healthcare equipment market. The company is becoming a leader in the precision radiation therapy market and has a positive market outlook. ARAY's innovative radiosurgery and radiation therapy systems play a crucial role in cancer treatment and have a large market to tap into, particularly in China and Brazil.
Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod
Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.
New Strong Sell Stocks for August 11th
NGLOY, ARAY and BANR have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2023.
Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates
Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.
Accuray (ARAY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
Accuray (ARAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates
Accuray (ARAY) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.01 per share a year ago.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
ARAY Financial details
ARAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.79 | 4.26 | 4.31 | 4.67 | 4.72 | |
| Net income per share | -0.19 | 0.04 | -0.07 | -0.06 | -0.1 | |
| Operating cash flow per share | -0.34 | -0.02 | 0.42 | -0.03 | 0.16 | |
| Free cash flow per share | -0.39 | -0.06 | 0.39 | -0.08 | 0.03 | |
| Cash per share | 0.88 | 1.2 | 1.26 | 0.96 | 0.94 | |
| Book value per share | 0.57 | 0.7 | 0.75 | 0.58 | 0.57 | |
| Tangible book value per share | -0.1 | 0.05 | 0.11 | -0.05 | -0.04 | |
| Share holders equity per share | 0.57 | 0.7 | 0.75 | 0.58 | 0.57 | |
| Interest debt per share | 2 | 2.67 | 2.35 | 2.41 | 2.16 | |
| Market cap | 341.99M | 182.44M | 415.98M | 180.51M | 367.2M | |
| Enterprise value | 425.03M | 296.57M | 499.02M | 305.5M | 482.84M | |
| P/E ratio | -20.81 | 57.81 | -65.91 | -33.76 | -39.57 | |
| Price to sales ratio | 0.82 | 0.48 | 1.05 | 0.42 | 0.82 | |
| POCF ratio | -11.54 | -124.2 | 10.8 | -75.21 | 23.63 | |
| PFCF ratio | -10.07 | -35.11 | 11.49 | -25.36 | 125.54 | |
| P/B Ratio | 6.86 | 2.91 | 6.04 | 3.39 | 6.84 | |
| PTB ratio | 6.86 | 2.91 | 6.04 | 3.39 | 6.84 | |
| EV to sales | 1.01 | 0.77 | 1.26 | 0.71 | 1.08 | |
| Enterprise value over EBITDA | 729.05 | 24.99 | 22.44 | 37.49 | 202.7 | |
| EV to operating cash flow | -14.34 | -201.89 | 12.96 | -127.29 | 31.07 | |
| EV to free cash flow | -12.52 | -57.07 | 13.79 | -42.93 | 165.07 | |
| Earnings yield | -0.05 | 0.02 | -0.02 | -0.03 | -0.03 | |
| Free cash flow yield | -0.1 | -0.03 | 0.09 | -0.04 | 0.01 | |
| Debt to equity | 3.21 | 3.53 | 2.9 | 4.02 | 3.82 | |
| Debt to assets | 0.36 | 0.45 | 0.42 | 0.45 | 0.43 | |
| Net debt to EBITDA | 142.45 | 9.62 | 3.73 | 15.34 | 48.54 | |
| Current ratio | 1.79 | 1.96 | 1.83 | 1.68 | 1.7 | |
| Interest coverage | -0.66 | 0.24 | 0.94 | 0.32 | 0 | |
| Income quality | 1.8 | -0.38 | -6.1 | 0.45 | -1.67 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.12 | 0.11 | 0.11 | 0.1 | 0.11 | |
| Research and developement to revenue | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | |
| Intangibles to total assets | 0.13 | 0.12 | 0.12 | 0.12 | 0.12 | |
| Capex to operating cash flow | 0.15 | 2.54 | -0.06 | 1.97 | -0.81 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | |
| Capex to depreciation | -0.41 | -0.49 | -0.36 | -0.86 | -2.79 | |
| Stock based compensation to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Graham number | 1.55 | 0.74 | 1.07 | 0.87 | 1.12 | |
| ROIC | -0.05 | 0.01 | 0.07 | 0.02 | 0.01 | |
| Return on tangible assets | -0.04 | 0.01 | -0.01 | -0.01 | -0.02 | |
| Graham Net | -1.91 | -2.06 | -1.82 | -2.05 | -2.19 | |
| Working capital | 151.89M | 174.37M | 160.41M | 142.03M | 139.4M | |
| Tangible asset value | -8.58M | 4.41M | 10.45M | -4.9M | -4.23M | |
| Net current asset value | -44.24M | -70.66M | -58.49M | -68.77M | -87.52M | |
| Invested capital | 3.21 | 3.53 | 2.9 | 4.02 | 3.82 | |
| Average receivables | 88.94M | 100.74M | 87.48M | 89.9M | 84.61M | |
| Average payables | 24.63M | 26.34M | 21.3M | 25.4M | 32.54M | |
| Average inventory | 114.68M | 127.67M | 130.23M | 134.09M | 143.7M | |
| Days sales outstanding | 97.52 | 85.4 | 78.62 | 80.18 | 60.98 | |
| Days payables outstanding | 42.13 | 36.22 | 30.01 | 42.37 | 41.94 | |
| Days of inventory on hand | 172.18 | 210.69 | 194.12 | 192.34 | 180.42 | |
| Receivables turnover | 3.74 | 4.27 | 4.64 | 4.55 | 5.99 | |
| Payables turnover | 8.66 | 10.08 | 12.16 | 8.61 | 8.7 | |
| Inventory turnover | 2.12 | 1.73 | 1.88 | 1.9 | 2.02 | |
| ROE | -0.33 | 0.05 | -0.09 | -0.1 | -0.17 | |
| Capex per share | -0.05 | -0.04 | -0.03 | -0.05 | -0.13 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q4
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.18 | 1.03 | 1.21 | 1.24 | 1.23 | |
| Net income per share | -0.04 | -0.06 | -0.02 | 0.01 | -0.03 | |
| Operating cash flow per share | -0.05 | 0 | -0.19 | 0.26 | 0.01 | |
| Free cash flow per share | -0.06 | -0.01 | -0.21 | 0.24 | 0.01 | |
| Cash per share | 0.95 | 0.87 | 0.72 | 0.93 | 0.93 | |
| Book value per share | 0.57 | 0.5 | 0.55 | 0.57 | 0.56 | |
| Tangible book value per share | -0.05 | -0.12 | -0.07 | -0.04 | -0.04 | |
| Share holders equity per share | 0.57 | 0.5 | 0.55 | 0.57 | 0.56 | |
| Interest debt per share | 2.33 | 2.22 | 2.22 | 2.16 | 2.14 | |
| Market cap | 182.37M | 194.54M | 197.65M | 283.7M | 371.31M | |
| Enterprise value | 307.37M | 318.85M | 337.3M | 399.66M | 486.94M | |
| P/E ratio | -13.21 | -8.93 | -26.37 | 118.41 | -36.32 | |
| Price to sales ratio | 1.66 | 2.02 | 1.72 | 2.4 | 3.14 | |
| POCF ratio | -39.27 | 4.23K | -10.97 | 11.52 | 373.92 | |
| PFCF ratio | -30.19 | -158.68 | -10.11 | 12.45 | 373.92 | |
| P/B Ratio | 3.43 | 4.14 | 3.82 | 5.19 | 6.92 | |
| PTB ratio | 3.43 | 4.14 | 3.82 | 5.19 | 6.92 | |
| EV to sales | 2.79 | 3.3 | 2.94 | 3.39 | 4.12 | |
| Enterprise value over EBITDA | 150.08 | -146.13 | 124.69 | 172.57 | -1.07K | |
| EV to operating cash flow | -66.19 | 6.93K | -18.72 | 16.23 | 490.37 | |
| EV to free cash flow | -50.89 | -260.07 | -17.25 | 17.54 | 490.37 | |
| Earnings yield | -0.02 | -0.03 | -0.01 | 0 | -0.01 | |
| Free cash flow yield | -0.03 | -0.01 | -0.1 | 0.08 | 0 | |
| Debt to equity | 4.02 | 4.37 | 4.01 | 3.75 | 3.82 | |
| Debt to assets | 0.45 | 0.44 | 0.44 | 0.43 | 0.43 | |
| Net debt to EBITDA | 61.03 | -56.97 | 51.63 | 50.07 | -253.03 | |
| Current ratio | 1.68 | 1.74 | 1.82 | 1.79 | 1.7 | |
| Interest coverage | 0.22 | -0.96 | 0.59 | 1.02 | 0 | |
| Income quality | 1.35 | -0.01 | 9.61 | 41.11 | -0.39 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.11 | 0.12 | 0.1 | 0.09 | 0.11 | |
| Research and developement to revenue | 0.13 | 0.15 | 0.13 | 0.12 | 0.12 | |
| Intangibles to total assets | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
| Capex to operating cash flow | 0.3 | -27.65 | 0.09 | -0.07 | 0 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | -0.02 | 0 | |
| Capex to depreciation | -1.1 | -1.08 | -1.33 | -1.67 | 0 | |
| Stock based compensation to revenue | 0.02 | 0.03 | 0.03 | 0.01 | 0.02 | |
| Graham number | 0.69 | 0.81 | 0.49 | 0.28 | 0.58 | |
| ROIC | 0.01 | -0.01 | 0.01 | 0 | 0 | |
| Return on tangible assets | -0.01 | -0.01 | 0 | 0 | -0.01 | |
| Graham Net | -2.03 | -2.18 | -2.16 | -2.08 | -2.16 | |
| Working capital | 142.03M | 142.73M | 152.23M | 151.09M | 139.4M | |
| Tangible asset value | -4.9M | -10.88M | -6.3M | -3.36M | -4.23M | |
| Net current asset value | -68.77M | -84.09M | -80.08M | -78.1M | -87.52M | |
| Invested capital | 4.02 | 4.37 | 4.01 | 3.75 | 3.82 | |
| Average receivables | 91.87M | 85.74M | 83.11M | 83.27M | 76.06M | |
| Average payables | 31.85M | 32.14M | 33.4M | 31.25M | 31.19M | |
| Average inventory | 139.89M | 147.44M | 154.14M | 153.12M | 147.87M | |
| Days sales outstanding | 77.25 | 71.85 | 69.94 | 58.97 | 56.89 | |
| Days payables outstanding | 42.09 | 47.9 | 42.45 | 32.5 | 37.67 | |
| Days of inventory on hand | 191.08 | 221.92 | 195.14 | 170.81 | 162.05 | |
| Receivables turnover | 1.16 | 1.25 | 1.29 | 1.53 | 1.58 | |
| Payables turnover | 2.14 | 1.88 | 2.12 | 2.77 | 2.39 | |
| Inventory turnover | 0.47 | 0.41 | 0.46 | 0.53 | 0.56 | |
| ROE | -0.06 | -0.12 | -0.04 | 0.01 | -0.05 | |
| Capex per share | -0.02 | -0.01 | -0.02 | -0.02 | 0 |
ARAY Frequently Asked Questions
What is Accuray Incorporated stock symbol ?
Accuray Incorporated is a US stock , located in Sunnyvale of Ca and trading under the symbol ARAY
Is Accuray Incorporated buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $7. The lowest prediction is $7 and the highest is $7
What is ARAY stock prediction ?
What is Accuray Incorporated stock quote today ?
Accuray Incorporated stock price is $2.71 today.
Is Accuray Incorporated stock public?
Yes, Accuray Incorporated is a publicly traded company.
Company Profile
- Volume Average 745.99K
- Market Capitalization 260.79M
- Employee 1.02K
- CEO Ms. Suzanne Winter M.B.A.
- Headquarters Sunnyvale,CA,US
- IPO Date 2007-02-08
-
Website
https://www.accuray.com 
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
